Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations

European Journal of Paediatric Neurology - Tập 22 - Trang 738-748 - 2018
Paolo Curatolo1, Rima Nabbout2, Lieven Lagae3, Eleonora Aronica4,5, Josè Carlos Ferreira6, Martha Feucht7, Christoph Hertzberg8, Anna C. Jansen9, Floor Jansen10, Katarzyna Kotulska11, Romina Moavero1,12, Finbar O'Callaghan13, Antigone Papavasiliou14, Michal Tzadok15, Sergiusz Jóźwiak16
1Child Neurology Unit, Systems Medicine Department, Tor Vergata University Hospital of Rome, Via Montpellier 1, 00133 Rome, Italy
2Centre de reference epilepsies rares, Service de Neurologie Pediatrique, Hopital Necker-Enfants Malades, Université Paris Descartes, 149 Rue de Sèvres, 75015 Paris, France
3Department of Development and Regeneration – Section Pediatric Neurology, University Hospitals KU Leuven, Leuven, Belgium
4Department of (neuro)pathology, Academisch Medisc Centrum, Meibergdreef 9, 1105 Amsterdam, The Netherlands
5SEIN – Stichting Epilepsie Instellingen Nederland, Heemstede, The Netherlands
6Neuro Pediatria, Centro Hospitalar Lisboa Ocidental, Hospital Sao Francisco Xavier, Lisbon, Portugal
7Department of Paediatrics, University Hospital Vienna, Vienna, Austria
8Diagnose und Behandlunszentrum fur Kinder und Jugendliche, Vivantes Klinikum Neukolln, Berlin, Germany
9Pediatric Neurology Unit, UZ Brussel, Brussels, Belgium
10Department of Child Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, The Netherlands
11Department of Neurology and Epileptology, The Children’s Memorial Health Institute, Warsaw, Poland
12Child Neurology Unit, Neuroscience and Neurorehabilitation Department, Bambino Gesù Children's Hospital, IRCCS, Piazza S. Onofrio, 4 00165 Rome, Italy
13Clinical Neuroscience Section, Institute of Child Health, University College London, London WC1N 1EH, UK
14Department of Pediatric Neurology, Penteli Children's Hospital, Athens, Greece
15Pediatric Neurology Institute, Sheba Medical Center, Tel HaShomer, Israel
16Department of Child Neurology, Medical University of Warsaw, Warsaw, Poland

Tài liệu tham khảo

Palavra, 2017, Recent advances and challenges of mTOR inhibitors use in treatment of patients with tuberous sclerosis complex, Oxid Med Cell Longev, 9820181, 1, 10.1155/2017/9820181

Curatolo, 2015, Neurological and neuropsychiatric aspects of tuberous sclerosis complex, Lancet Neurol, 14, 733, 10.1016/S1474-4422(15)00069-1

Chu-Shore, 2010, The natural history of epilepsy in tuberous sclerosis complex, Epilepsia, 51, 1236, 10.1111/j.1528-1167.2009.02474.x

Kingswood, 2017, TuberOus SClerosis registry to increase disease awareness (TOSCA) − baseline data on 2093 patients, Orphanet J Rare Dis, 12, 2, 10.1186/s13023-016-0553-5

Davis, 2017, Presentation and diagnosis of tuberous sclerosis complex in infants, Pediatrics, 140, 10.1542/peds.2016-4040

de Vries, 2015, Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist, Pediatr Neurol, 52, 25, 10.1016/j.pediatrneurol.2014.10.004

O'Callaghan, 2004, The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex, Arch Dis Child, 89, 530, 10.1136/adc.2003.026815

Staley, 2008, Self-injurious behavior and tuberous sclerosis complex: frequency and possible associations in a population of 257 patients, Epilepsy Behav, 13, 650, 10.1016/j.yebeh.2008.07.010

Winterkorn, 2007, Cognitive prognosis of patients with tuberous sclerosis complex, Neurology, 68, 62, 10.1212/01.wnl.0000250330.44291.54

Gipson, 2017, New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND), F1000 Res., 6

Capal, 2017, Influence of seizures on early development in tuberous sclerosis complex, Epilepsy Behav, 70, 245, 10.1016/j.yebeh.2017.02.007

Cusmai, 2011, Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis, Epilepsy Behav, 22, 735, 10.1016/j.yebeh.2011.08.037

Jóźwiak, 2011, Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex, Eur J Paediatr Neurol, 15, 424, 10.1016/j.ejpn.2011.03.010

Curatolo, 2012, Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations, Eur J Paediatr Neurol, 16, 582, 10.1016/j.ejpn.2012.05.004

White, 2002, Animal models of epilepsy, Neurology, 59, S7, 10.1212/WNL.59.9_suppl_5.S7

Pitkänen, 2010, Therapeutic approaches to epileptogenesis−hope on the horizon, Epilepsia, 51, 2, 10.1111/j.1528-1167.2010.02602.x

Pitkänen, 2014, Past and present definitions of epileptogenesis and its biomarkers, Neurotherapeutics, 11, 231, 10.1007/s13311-014-0257-2

Pitkänen, 2015, Epileptogenesis, Cold Spring Harb Perspect Med., 5, 10.1101/cshperspect.a022822

Slovatir, 2017, Epileptogenesis meets Occam's razor, Curr Opin Pharmacol, 35, 105, 10.1016/j.coph.2017.07.012

Curatolo, 2016, Early onset epileptic encephalopathy or genetically determined encephalopathy with early onset epilepsy? Lessons learned from TSC, Eur J Paediatr Neurol, 20, 203, 10.1016/j.ejpn.2015.12.005

Domanska-Pakiela, 2014, EEG abnormalities preceding the epilepsy onset in tuberous sclerosis complex patients. A prospective study of 5 patients, Eur J Paediatr Neurol, 18, 458, 10.1016/j.ejpn.2013.12.006

Wu, 2016, Clinical encephalographic biomarker for impending epilepsy in asymptomatic tuberous sclerosis complex infants, Pediatr Neurol, 54, 29, 10.1016/j.pediatrneurol.2015.09.013

Potential EEG biomarkers and antiepileptogenic strategies for epilepsy in TSC.Available at: https://clinicaltrials.gov/ct2/show/NCT01767779?term=epilepsy&cond=tuberous+sclerosis&rank=4. Last accessed: May 30, 2018.

Slowińska, 2018, Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures?, Orphanet J Rare Dis, 13, 25, 10.1186/s13023-018-0764-z

Chung, 2017, Early detection of tuberous sclerosis complex: an opportunity for improved neurodevelopmental outcome, Pediatr Neurol, 76, 20, 10.1016/j.pediatrneurol.2017.05.014

Whitney, 2017, The utility of surveillance electroencephalography to guide early antiepileptic drug therapy in infants with tuberous sclerosis complex, Pediatr Neurol, 72, 76, 10.1016/j.pediatrneurol.2017.04.009

Bombardieri, 2010, Early control of seizures improves long-term outcome in children with tuberous sclerosis complex, Eur J Paediatr Neurol, 14, 177, 10.1016/j.ejpn.2009.03.003

Staley, 2011, Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs, Pediatrics, 127, 117, 10.1542/peds.2010-0192

Chiron, 1997, Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis, Epilepsy Res, 26, 389, 10.1016/S0920-1211(96)01006-6

Elterman, 2001, Randomized trial of vigabatrin in patients with infantile spasms, Neurology, 57, 1416, 10.1212/WNL.57.8.1416

EPISTOP. Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – tuberous sclerosis complex. Available at: https://clinicaltrials.gov/ct2/show/NCT02098759?term=epistop&cond=tuberous+sclerosis+complex&rank=1. Last accessed: May 30, 2018.

PREVeNT. Preventing epilepsy using vigabatrin in infants with tuberous sclerosis complex. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02849457?term=prevent+and+tsc&rank=1. Last accessed: May 30, 2018.

Benvenuto, 2017, Prospective serial neuropsychological study in infants with tuberous sclerosis complex (TSC): first Analysis from the EPISTOP Project, Eur J Paediatr Neurol, 21, e23, 10.1016/j.ejpn.2017.04.1142

Overwater, 2015, Epilepsy in children with tuberous sclerosis complex: chance of remission and response to antiepileptic drugs, Epilepsia, 56, 1239, 10.1111/epi.13050

Riikonen, 2015, Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study, Dev Med Child Neurol, 57, 60, 10.1111/dmcn.12573

Schwarz, 2016, A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: the UCLA experience, Epilepsy Behav, 57, 29, 10.1016/j.yebeh.2016.01.012

Muzykewicz, 2009, Infantile spasms in tuberous sclerosis complex: prognostic utility of EEG, Epilepsia, 50, 290, 10.1111/j.1528-1167.2008.01788.x

Iyer, 2016, Improving outcomes in infantile spasms, Paediatr Drugs., 18, 357, 10.1007/s40272-016-0188-y

Reddy, 2016, The pharmacological basis of cannabis therapy for epilepsy, J Pharmacol Exp Therapeut, 357, 45, 10.1124/jpet.115.230151

Hess, 2016, Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex, Epilepsia, 57, 1617, 10.1111/epi.13499

Aguirre-Velázquez, 2017, Survey report on parents and patients related to the use of cannabidiol symptomatic epilepsy secondary to tuberous sclerosis complex (TSC) in Mexico, J Adv Med Med Res, 23, 1, 10.9734/JAMMR/2017/36585

GWP42003-P, CBD. A randomized controlled trial of cannabidiol for seizures in tuberous sclerosis complex. Available at: https://clinicaltrials.gov/ct2/show/NCT02544763?term=epilepsy&cond=tuberous+sclerosis&rank=13. Last accessed: May 30, 2018.

GWPCARE6. An open-label extension trial of cannabidiol (GWP42003-P, CBD) for seizures in tuberous sclerosis complex. Available at: https://clinicaltrials.gov/ct2/show/NCT02544750?term=epilepsy&cond=tuberous+sclerosis&rank=14. Last accessed: May 30, 2018.

Crino, 2016, The mTOR signalling cascade: paving new roads to cure neurological disease, Nat Rev Neurol, 12, 379, 10.1038/nrneurol.2016.81

Curatolo, 2015, Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy, Pediatr Neurol, 52, 281, 10.1016/j.pediatrneurol.2014.10.028

MacKeigan, 2015, Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex, Neuro Oncol, 17, 1550, 10.1093/neuonc/nov152

Krueger, 2013, Everolimus treatment of refractory epilepsy in tuberous sclerosis complex, Ann Neurol, 74, 679, 10.1002/ana.23960

Krueger, 2016, Long-term treatment of epilepsy with everolimus in tuberous sclerosis, Neurology, 87, 1, 10.1212/WNL.0000000000003400

Overwater, 2016, Sirolimus for epilepsy in children with tuberous sclerosis complex: a randomized controlled trial, Neurology, 87, 1011, 10.1212/WNL.0000000000003077

Samueli, 2016, Efficacy and safety of everolimus in children with TSC-associated epilepsy – pilot data from an open single-center prospective study, Orphanet J Rare Dis, 11, 145, 10.1186/s13023-016-0530-z

French, 2016, Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study, Lancet, 388, 2153, 10.1016/S0140-6736(16)31419-2

Curatolo, 2018

A pilot study to evaluate the effects of everolimus on brain mTOR activity and cortical hyperexcitability in TSC and FCD. Available at: https://clinicaltrials.gov/ct2/show/NCT02451696?term=epilepsy&cond=tuberous+sclerosis&rank=7. Last accessed: May 30, 2018.

European Medicines Agency. Votubia (everolimus): summary of opinion. December 15, 2016. Available at: ema.europa.eu.

Mingarelli, 2018, Dramatic relapse of seizures after everolimus withdrawal, Eur J Paediatr Neurol, 22, 203, 10.1016/j.ejpn.2017.07.018

Moavero, 2013, Is mTOR inhibition a systemic treatment for tuberous sclerosis?, Ital J Pediatr, 39, 57, 10.1186/1824-7288-39-57

Krueger, 2017, Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders, Ann Clin Transl Neurol, 4, 877, 10.1002/acn3.494

Cross, 2006, Proposed criteria for referral and evaluation of children for epilepsy surgery: recommendations of the Subcommission for Pediatric Epilepsy Surgery, Epilepsia, 47, 952, 10.1111/j.1528-1167.2006.00569.x

Gupta, 2017, Epilepsy surgery in tuberous sclerosis complex: in pursuit of the epileptogenic center(s), Epilepsia, 17, 150

Wu, 2010, Noninvasive testing, early surgery, and seizure freedom in tuberous sclerosis complex, Neurology, 74, 392, 10.1212/WNL.0b013e3181ce5d9e

Arya, 2015, Long-term outcomes of resective epilepsy surgery after invasive presurgical evaluation in children with tuberous sclerosis complex and bilateral multiple lesions, J Neurosurg Pediatr, 15, 26, 10.3171/2014.10.PEDS14107

Jansen, 2007, Epilepsy surgery in tuberous sclerosis: the Dutch experience, Seizure, 16, 445, 10.1016/j.seizure.2007.03.001

Fallah, 2013, Predictors of seizure outcomes in children with tuberous sclerosis complex and intractable epilepsy undergoing resective epilepsy surgery: an individual participant data meta-analysis, PLoS One, 8, 10.1371/journal.pone.0053565

Zhang, 2013, Predictors of seizure freedom after surgical management of tuberous sclerosis complex: a systematic review and meta-analysis, Epilepsy Res, 105, 377, 10.1016/j.eplepsyres.2013.02.016

Fallah, 2015, Resective epilepsy surgery for tuberous sclerosis in children: determining predictors of seizure outcomes in a multicenter retrospective cohort study, Neurosurgery, 77, 517, 10.1227/NEU.0000000000000875

Liang, 2017, Long-term outcomes of epilepsy surgery in tuberous sclerosis complex, J Neurol, 264, 1146, 10.1007/s00415-017-8507-y

McDaniel, 2011, The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway, Epilepsia, 52, e7, 10.1111/j.1528-1167.2011.02981.x

Park, 2017, Ketogenic diet for the management of epilepsy associated with tuberous sclerosis complex in children, J Epilepsy Res, 7, 45, 10.14581/jer.17008

Ville, 2015, The ketogenic diet can be used successfully with corticosteroids for epileptic encephalopathies, Epilepsy Behav, 48, 61, 10.1016/j.yebeh.2015.03.003

Major, 2008, Vagus nerve stimulation for intractable epilepsy in tuberous sclerosis complex, Epilepsy Behav, 13, 357, 10.1016/j.yebeh.2008.04.001

Elliott, 2009, Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery, Epilepsy Behav, 16, 454, 10.1016/j.yebeh.2009.08.018

Parain, 2001, Vagal nerve stimulation in tuberous sclerosis patients, Pediatr Neurol, 25, 213, 10.1016/S0887-8994(01)00312-5

Zamponi, 2010, Vagus nerve stimulation for refractory epilepsy in tuberous sclerosis, Pediatr Neurol, 43, 29, 10.1016/j.pediatrneurol.2010.03.003

Orosz, 2014, Vagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24 months in 347 children, Epilepsia, 55, 1576, 10.1111/epi.12762

Fallah, 2016, Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with tuberous sclerosis complex, Epilepsy Behav, 63, 79, 10.1016/j.yebeh.2016.07.034

A pilot study to evaluate the effects of everolimus on brain mTOR activity and cortical hyperexcitability in TSC and FCD. Available at: https://clinicaltrials.gov/ct2/show/NCT02451696?term=seizures&cond=tsc&draw=2&rank=12. Last accessed: April 10, 2018.

Application of novel diagnostic and therapeutical methods in epilepsy and neurodevelopmental abnormalities in children (EPIMARKER). Available at: https://clinicaltrials.gov/ct2/show/NCT03486366?term=seizures&cond=tsc&draw=3&rank=17. Last accessed: April 10, 2018.

Thông tin
Thông tin xuất bản

European Journal of Paediatric Neurology

Tập 22

738-748

Thông tin tác giả